TaiRx, Inc. (6580.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$12.85 (+0.39%) as of
Key statistics
- Market cap
- 1.44B
- EPS (TTM)
- -2.09
- Dividend yield
- 0.00%
- 52-week range
- 11.95 – 24.75
- Beta
- 0.37
- Revenue (TTM)
- 29.44M
- Profit margin
- 0.00%
- Volume
- 18.03k
About TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.